DENVER--(BUSINESS WIRE)--

Cannabis Science, Inc. (OTCBB: CBIS.OB - News), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that it has signed a major multi-company acquisition agreement that will boost revenues, strengthen pharmaceutical operations and our management team.

These additions will enhance our internal operations and help to fast track our full line of Cannabis Science Brand pharmaceutical and over the counter products through multiple distribution channels to be made available nationally. Over the coming days there will be several announcements outlining the outstanding growth opportunities that will be enhanced by these deals.

Cannabis Science Inc., President & CEO, Dr Robert Melamede Ph.D., stated, “These deals put Cannabis Science in a very strong position to grow our Company quickly. We have increased our corporate structure to handle the impressive growth opportunities that are unfolding before us. We have already begun a limited production of the Cannabis Science brand product line with their successful therapeutic functionality demonstrated by the case studies of cancer patients that are posted on the Cannabis Science homepage (http://www.cannabisscience.com).

It has taken time and effort to develop many important relationships, the first of which are now coming to fruition. These advancements will take Cannabis Science to the next level with multiple products that will have multiple distribution channels nationwide. These deals include strategic relationships with pharmacists and the exclusive production of organically grown strains for our scientific medicinal formulations. Additional accessory businesses will include laboratory capacity for product quality assurance and testing, and educational platforms to produce and distribute information about the science of cannabis that will further our cause through education.”

The main elements of this group of deals are the following:

1. New Executive Management Appointments

2. Licensing agreement for exclusive strains, lab facilities, and commercial manufacturing.

3. A “Cannabis University” acquisition to be converted to Cannabis Science Brand

4. New Cannabis Science Brand product lines

5. Multiple national product distribution channels

6. Focused continued growth plan based on operational expertise and market opportunities

7. Critical ailment target expansions

Apothecary Genetics, a cannabis seed breeding company signed a licensing agreement with Cannabis Science. Apothecary will produce several Cannabis Science Brand Formulations for the California medical cannabis market. As well, Apothecary will provide research and development facilities with full circle operations including a California laboratory facility for internal research and development, along with 16 unique genetic strains specifically generated and maintained by a cancer survivor who recognizes the importance of proper growth and breeding.

GGECO University, an online video-based medical cannabis education system, offering courses dealing with medical cannabis law, the benefits of medical marijuana, cooking, horticulture, and bud tending, has been acquired by Cannabis Science, following the university‘s name to Cannabis Science University. Cannabis Science hopes to use this platform to educate the general public, patients, and even those who have already been involved in the medical cannabis industry on the medical benefits of cannabis, how it is grown, how to use it safely, and the many applications or ways to administer the medication.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
            1-888-889-0888      
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
Investor Relations Management
            1-561-234-6929      
info@cannabisscience.com
www.cannabisscience.com